Corrigendum to “A randomized, double-blind, placebo-controlled clinical trial of 8-week intranasal oxytocin administration in adults with obesity: Rationale, study design, and methods” [Contemporary Clinical Trials 122 (2022) 1-11/106909]
Marie‐Louis Wronski(Harvard University), Elizabeth A. Lawson(Harvard University), Liya Kerem(Harvard University), Martin Torriani(Harvard University), Fatima Cody Stanford(Massachusetts General Hospital), Elisa Asanza(Harvard University), Laura M. Holsen(Brigham and Women's Hospital), Mark Vangel(Massachusetts General Hospital), Alexander A. Soukas(Broad Institute), Tara M. Holmes(Harvard University), Thilo Deckersbach(Massachusetts General Hospital), Miriam A. Bredella(Massachusetts General Hospital), Michelle L. O’Donoghue(Brigham and Women's Hospital), Franziska Plessow(Harvard University), Kamryn T. Eddy(Harvard University), Arvin Kheterpal(Harvard University)
Cited by 0
Related Papers
Definition and diagnostic criteria of clinical obesity
|The Lancet Diabetes & Endocrinology|2025|1.3k
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk
|Circulation|2019|930
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|877
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials
|The Lancet|2009|723
Leptin-specific patterns of gene expression in white adipose tissue
|Genes & Development|2000|527